Glaxo’s Medicaid position
Executive Summary
Glaxo did not support Merck's "best price" plan at the PMA board meeting on May 3. The company's board representative, Charles Sanders, reportedly commented favorably on the open access part of the suggestion. Glaxo is not, however, taken with the Defense Department discount formula. Glaxo is believed to be investigating other potential discount formulas for the Medicaid business.